FDA approves landmark pancreatic cancer drug that’s shown to improve survival
The FDA has approved 'daraxonrasib', a new pill for advanced pancreatic cancer that has shown to nearly double survival times in clinical trials. The drug, branded as Rasonque, targets a specific mutated protein and represents a significant advancement in treatment.
Why it matters
It offers a breakthrough treatment option for one of the most lethal forms of cancer, though high costs remain a point of concern.
The Food and Drug Administration on Wednesday approved a groundbreaking new drug for advanced pancreatic cancer, offering U.S. patients a more effective treatment against one of the deadliest types of cancer.
The article provides a balanced report on medical approval, efficacy, and cost.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in